A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI

Contrast-induced Acute Kidney Injury Clinical Trial

Official title:

A Multicenter, Randomized, Open-label Phase II Clinical Trial Evaluating Alprostadil Liposomal Injection in the Prevention of Contrast-induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05475717
• Other study ID #: HF1307-004
• Status: Recruiting
• Phase: Phase 2
• Start date: October 20, 2022
• Est. completion date: May 2024

Study information

• Verified date: October 2022
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: Yong Huo, professor
• Phone: +86-010-83572283
• Email: huoyong[@]263.net.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, open-label phase II clinical trial to evaluate alprostadil liposomal injection in the prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.

Description:

The trial is a multicenter, randomized, open-label, two-stage study. The trial period includes a screening period (up to 14 days), a treatment period (4 days), and a safety follow-up period (7 days ± 3 days). At least 368 patients with pre-PCI (percutaneous coronary intervention) are expected to be included, and all patients will be contrasted with non-ionic hypotonic/isotonic contrast media.

The trail will be divided into two stages. Three dose groups are set in the first stage: 20 µg/day, 40 µg/day and 80 µg/day. In the first stage, on the basis of hydration prevention, patients will randomized to receive 20, 40 or 80 µg/day of alprostadil liposome injection for 4 days (1 to 3 hours before surgery and 3 days after surgery), once a day. The blank control group will only receive hydration prophylaxis. In the second stage, according to the comprehensive evaluation of the data in the first stage, a dose group will be selected to continue to be enrolled. The primary outcome measure is the incidence of contrast-induced acute kidney injury within 72 hours after PCI. During the administration of alprostadil liposomal injection, vital signs, physical examination, ECOG performance status, laboratory test, ECG, adverse events and PK parameters will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 368
• Est. completion date: May 2024
• Est. primary completion date: February 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Agree to participate in this clinical trial and sign the informed consent voluntarily; 2.18=age=80 years old, gender is not limited; 3.Suffering from coronary artery disease and preparing to undergo elective PCI; 4.Serum creatinine>1.5 mg/dL or 30=eGFR<60 mL/(min·1.73m^2), and meet at least one of the following risk factors:

1. Cardiac function class NYHA class III;

2. Age > 75 years old;

3. Anemia (baseline hematocrit: <36% in women, <39% in men);

4. Diabetes.

Exclusion Criteria:

1. Pre-perform emergency PCI;

2. Previously allergic to alprostadil similar products and contrast agents; used alprostadil within 3 days before the first administration;

3. Severe renal insufficiency: renal replacement therapy may be performed in a short period of time or eGFR<30 mL/(min·1.73m^2);

4. Severe heart failure (LVEF <35% or NYHA class IV), acute heart failure, and pulmonary edema;

5. Requires mechanical circulatory support therapy (intra-aortic balloon pump, catheter-based ventricular assist device, venous-arterial extracorporeal membrane oxygenation therapy, etc.);

6. Hypotension: systolic blood pressure < 90 mmHg;

7. Acute bleeding disorders or bleeding tendency, and the investigators believe that they are not suitable to participate in this trial;

8. Severe anemia (hemoglobin <60 g/L);

9. Active hepatitis B virus infection (positive hepatitis B virus surface antigen and the quantitative detection value of hepatitis B virus DNA exceeds the upper limit of the normal range of the research center), positive for any one of hepatitis C virus antibody, HIV antibody, and Treponema pallidum antibody;

10. Abnormal liver function (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 3 times the upper limit of normal);

11. Contrast agents or known nephrotoxic drugs (aminoglycoside antibiotics, amphotericin B, vancomycin, antiviral drugs, non-steroidal anti-inflammatory drugs (except aspirin), Immunosuppressants, traditional Chinese medicines and proprietary Chinese medicines containing aristolochic acid, etc.) within 14 days before the first application of the test drug, or the use of drugs that protect the kidneys against AKI (N-acetylcysteine, sodium bicarbonate, aminophylline) within 3 days before the first application of the test drug;

12. Severe renal artery stenosis, and in the opinion of the the investigator, is unsuitable to participate in this trial;

13. Electrolyte disorders (serum potassium <2.5 mmol/L or serum sodium <125 mmol/L);

14. A history of glaucoma or ocular hypertension or gastric ulcer;

15. Interstitial pneumonia or mental illness or dementia;

16. Malignant tumors;

17. Have participated in drug clinical trials and used drugs within 3 months before screening;

18. Pregnant or breastfeeding, or patients who cannot use effective contraception during the study;

19. Other patients deemed unsuitable for participation in this trial by the investigator.

Related Conditions & MeSH terms

• Acute Kidney Injury
• Contrast-induced Acute Kidney Injury

Intervention

Drug:
• Alprostadil liposome injection
Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)

Locations

Country	Name	City	State
China	Beijing University First Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of contrast-induced acute kidney injury within 72 hours after PCI	Incidence of contrast-induced acute kidney injury within 72 hours after PCI	from baseline to 72 hours after PCI
Secondary	Changes in serum creatinine from baseline at 24 hours, 48 hours, and 72 hours after angiography	Changes in serum creatinine from baseline at 24 hours, 48 hours, and 72 hours after angiography	from baseline to 72 hours after angiography
Secondary	Changes in blood urea nitrogen from baseline at 24 hours, 48 hours, and 72 hours after angiography	Changes in blood urea nitrogen from baseline at 24 hours, 48 hours, and 72 hours after angiography	from baseline to 72 hours after angiography
Secondary	Changes in cystatin C from baseline at 24 hours, 48 hours, and 72 hours after angiography	Changes in cystatin C from baseline at 24 hours, 48 hours, and 72 hours after angiography	from baseline to 72 hours after angiography
Secondary	Changes in hs-CRP from baseline at 24 hours, 48 hours, and 72 hours after angiography	Changes in hs-CRP from baseline at 24 hours, 48 hours, and 72 hours after angiography	from baseline to 72 hours after angiography
Secondary	Changes in IL-6 from baseline at 24 hours, 48 hours, and 72 hours after angiography	Changes in IL-6 from baseline at 24 hours, 48 hours, and 72 hours after angiography	from baseline to 72 hours after angiography
Secondary	Incidence of renal replacement therapy after angiography during the study period	Incidence of renal replacement therapy after angiography during the study	from baseline to 7 days after last dose
Secondary	Adverse events	Adverse events from baseline to 7 days after last dose, including symptoms, Abnormal laboratory test	from baseline to 7 days after last dose
Secondary	Incidence of major adverse cardiovascular events (MACE) during the study period (recurrent angina, nonfatal myocardial infarction, acute heart failure, ventricular fibrillation, cardiac death)	Incidence of major adverse cardiovascular events (MACE) during the study period (recurrent angina, nonfatal myocardial infarction, acute heart failure, ventricular fibrillation, cardiac death)	from baseline to 7 days after last dose